文献速递认知障碍与痴呆

血浆p-tau217浓度、APOE基因型与认知障碍发生时机:多种族汇总分析

Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies.
PubMed 文献 · Lancet Neurol · 2026-09-09

该研究汇总7个前瞻性队列8582名老年人的个体数据,评估APOE-ε4是否在血浆p-tau217浓度之外提供额外预后信息。结果显示,较高的p-tau217与认知障碍风险增加相关,且APOE-ε4携带者中关联更强、认知障碍发生时间更短。

要点

  • 血浆p-tau217升高与认知障碍风险增加相关,APOE-ε4携带者中关联更强。
  • APOE-ε4携带者中p-tau217每升高1个标准差,认知障碍发生时间缩短24%。
  • p-tau217与APOE基因型联合可用于无症状高风险个体的风险分层和时机估计。

核心结论

  • 血浆p-tau217浓度结合APOE基因型可能有助于对无症状阿尔茨海默病高风险个体进行风险分层和认知障碍时机估计。

研究设计与样本

  • 研究为7个多种族前瞻性队列的参与者水平数据汇总分析,纳入8582名有血浆p-tau217测量和临床数据的老年人。
  • 基线分析纳入全部合格参与者,纵向分析限制于基线无认知障碍且有至少一次随访评估的4569名参与者。

主要发现

  • p-tau217浓度每升高1-SD,APOE-ε4携带者认知障碍发生时间缩短24%,非携带者缩短13%。
  • 按p-tau217浓度分层的无认知障碍生存差异在生物标志物评估后3-4年、症状出现前显现。

关键数值与推荐

  • 认知障碍定义为轻度认知障碍或痴呆。
  • p-tau217作为连续变量建模,关联分析使用logistic回归和Cox模型,按APOE-ε4分层并纳入交互项。

临床怎么用

  • 对于无症状但阿尔茨海默病风险增加者(如有痴呆家族史或已知APOE-ε4携带状态),可考虑联合血浆p-tau217和APOE基因型进行风险分层和认知障碍时机估计。
  • 研究结果支持在临床前阶段对适当选择的高风险个体采用生物标志物指导的监测和治疗干预。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma tau phosphorylated at threonine 217 (p-tau217), a biomarker of Alzheimer's disease neuropathological changes, can increase before overt symptoms occur. However, individuals with similar p-tau217 concentrations but different genetic backgrounds might differ in their risk or timing of cognitive decline. We aimed to determine whether APOE genotype provides additional prognostic information beyond plasma p-tau217 concentration for estimating the risk and timing of cognitive impairment. METHODS: We did a pooled analysis of participant-level data from seven multi-ethnic prospective cohorts of older adults, including individuals with no cognitive impairment at increased risk of dementia and individuals with mild cognitive impairment or dementia, recruited through academic research centres and community-based settings in Canada, Dominican Republic, and USA. Data were collected from 1992 to 2025. This study included data from participants with plasma p-tau217 measurements, clinical cognitive status, APOE genotype, and complete covariate data. The primary outcome was cognitive impairment, defined as mild cognitive impairment or dementia. Baseline analyses included all eligible participants; longitudinal analyses were restricted to participants with no cognitive impairment at baseline and with at least one follow-up clinical assessment. We evaluated whether APOE-ε4 carrier status modified the risk and timing of cognitive impairment associated with plasma p-tau217 concentration modelled as a continuous variable. Associations of baseline p-tau217 concentration with prevalent and incident cognitive impairment were assessed using logistic regression and Cox models, stratified by APOE-ε4 and with interaction terms. Timing and prognostic performance were evaluated using survival analyses, discrimination measures, and random survival forests. FINDINGS: Among 8873 participants with available plasma p-tau217 concentration and clinical data who were examined for eligibility, 8582 participants (5652 [65·9%] female and 2930 [34·1%] male) were included in the baseline analysis. Mean age was 70 years (SD 10), and 1380 (16·1%) were Black, 4056 (47·3%) were non-Hispanic White, and 3146 (36·7%) were of Hispanic or other ethnic origin. 4569 (53·2%) participants had no cognitive impairment at baseline and were included in the longitudinal analysis. At baseline, higher p-tau217 concentrations were associated with cognitive impairment (odds ratio 1·77, 95% CI 1·42-2·20) and this association was stronger in APOE-ε4 carriers (2·25, 1·52-3·34) than in non-carriers (1·52, 1·35-1·72). Higher p-tau217 concentrations at baseline were also associated with incident cognitive impairment (hazard ratio 1·41, 95% CI 1·22-1·64; for 1-SD increase of p-tau217 levels), with a stronger association in APOE-ε4 carriers (1·76, 1·36-2·26) than in non-carriers (1·26, 1·12-1·42). Each 1-SD increase in p-tau217 concentration was associated with a 24% shorter time to cognitive impairment among APOE-ε4 carriers, compared with 13% among non-carriers. Differences in cognitive-impairment-free survival by p-tau217 concentration emerged 3-4 years after biomarker assessment and before symptom onset. INTERPRETATION: Plasma p-tau217 concentrations, considered together with APOE genotype, might help stratify risk and estimate the timing of future cognitive impairment in asymptomatic individuals who are at increased risk for Alzheimer's disease, such as those with a family history of dementia or known APOE-ε4 carrier status. These findings support the use of biomarker-informed approaches to guide monitoring and therapeutic intervention in appropriately selected at-risk individuals before the onset of clinical symptoms. FUNDING: National Institutes of Health.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Xu Y, Gunasekaran TI, Gu Y, et al. Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies. Lancet Neurol. 2026. PMID: 42716078. doi:10.1016/S1474-4422(26)00313-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。